secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stereotaxis, Inc. (STXS)
CIK:        0001289340
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001493152-23-027465
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stereotaxis Q2 revenue $7.9M (+28% YoY), net loss $5.0M, cash $23.9M
--------------------------------------------------------------------

- Revenue $7.9M, up 28% YoY; system revenue $3.3M (two Genesis systems), recurring revenue $4.6M.
- Gross margin 53%; operating loss ($5.3M), net loss ($5.0M); adjusted net loss ($2.4M).
- Cash $23.9M, no debt; expects year-end cash $22-24M; no additional financing needed.
- Orders for two Genesis systems in Q2; system backlog $16M; guidance of double-digit revenue growth in 2023.
- Announced strategic Abbott collaboration for EnSite X integration; MAGiC catheter study submitted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1289340/000149315223027465/0001493152-23-027465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1289340/000149315223027465/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer